← 治験一覧に戻る
TAS-114とS-1の併用療法とS-1単独療法を比較するランダム化第2相試験
基本情報
- NCT ID
- NCT02855125
- ステータス
- 完了
- 試験のフェーズ
- 第2相
- 試験タイプ
- 介入
- 目標被験者数
- 128
- 治験依頼者名
- Taiho Oncology, Inc.
概要
This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in patients with advanced or metastatic NSCLC. The study will be conducted internationally in 2 regions: Asian \[Japan\] and Western \[Europe and US\]. Patients will be randomized into TAS-114/S-1 arm versus S-1 control arm in a 1:1 ratio.
対象疾患
Advanced or Metastatic Non-small Cell Lung Cancer
介入
TAS-114(DRUG)
S-1(DRUG)
依頼者(Sponsor)
大鵬薬品工業株式会社(INDUSTRY)